AWM
TCRT icon

Act Wealth Management’s Alaunos Therapeutics TCRT Stock Holding History

Act Wealth Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-257
Closed -$19.6K – 43
2023
Q2 		$19.6K Hold
257
– – 0.01% 45
2023
Q1 		$24.2K Buy
+257
New +$24.5K 0.01% 44
2022
Q4 		– Sell
-257
Closed -$66K – 44
2022
Q3 		$66K Buy
257
+10
+4% +$2.9K 0.05% 37
2022
Q2 		$46K Hold
247
– – 0.03% 38
2022
Q1 		$24K Hold
247
– – 0.01% 41
2021
Q4 		$40K Buy
247
+17
+7% +$3.74K 0.02% 36
2021
Q3 		$91K Hold
230
– – 0.06% 33
2021
Q2 		$91K Buy
230
+5
+2% +$2.33K 0.06% 34
2021
Q1 		$121K Buy
225
+8
+4% +$4.98K 0.08% 34
2020
Q4 		$82K Buy
+217
New +$86.3K 0.05% 28

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Act Wealth Management's TCRT Position: Q3 2023 in Review

Act Wealth Management sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 257 shares — an estimated $19.6K sold.

Act Wealth Management first reported a position in TCRT in Q4 2020 and held it in 10 quarters. The position peaked at $121K in Q1 2021. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.

  • Act Wealth Management reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Act Wealth Management sold 257 Alaunos Therapeutics shares in Q3 2023, an estimated $19.6K.
  • Act Wealth Management first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 10 quarters.
  • Act Wealth Management's Alaunos Therapeutics position peaked at $121K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.

Based on Act Wealth Management's 13F filing for Q3 2023, filed 11 Oct 2023.